About 9 results found for searched term "CCR5 antagonist 1" (0.124 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M22004 | CCR5 antagonist 1 | Others |
| CCR5 antagonist 1 | ||
| M1971 | Maraviroc | CCR |
| Selzentry, Celsentri, UK-427857 | ||
| Maraviroc (UK-427857) is a selective CCR5 antagonist with potent anti-human immunodeficiency virus type 1 (HIV-1) activity and favorable pharmacological properties. | ||
| M9444 | Cenicriviroc Mesylate | CCR |
| TBR-652 Mesylate; TAK-652 Mesylate | ||
| Cenicriviroc Mesylate is a dual CCR2/CCR5 antagonist, and it also inhibits both HIV-1 and HIV-2. | ||
| M13927 | TAK-220 | CCR |
| TAK-220 is a selective and orally bioavailable CCR5 antagonist, with IC50s of 3.5 nM and 1.4 nM for inhibition on the binding of RANTES and MIP-1α to CCR5, respectively, but shows no effect on the binding to CCR1, CCR2b, CCR3, CCR4, or CCR7; TAK-220 also selectively inhibits HIV-1, with EC50s of 1.2 nM (HIV-1 KK), 0.72 nM (HIV-1 CTV), 1.7 nM (HIV-1 HKW), 1.7 nM (HIV-1 HNK), 0.93 nM (HIV-1 HTN), and 0.55 nM (HIV-1 HHA). | ||
| M13928 | CCR2 antagonist 4 | CCR |
| Teijin compound 1 | ||
| CCR2 antagonist 4 (Teijin compound 1) is a potent and specific CCR2 antagonist, with IC50s of 180 nM for CCR2b. CCR2 antagonist 4 potently inhibits MCP-1-induced chemotaxis with an IC50 of 24 nM. | ||
| M30118 | Aplaviroc hydrochloride | CCR |
| AK602 hydrochloride; GSK-873140 hydrochloride; GW-873140 hydrochloride | ||
| Aplaviroc (AK 602) hydrochloride, a SDP derivative, is a CCR5 antagonist, with IC50s of 0.1-0.4 nM for HIV-1Ba-L, HIV-1JRFL and HIV-1MOKW. | ||
| M30120 | Aplaviroc | CCR |
| AK 602; GSK 873140; GW 873140 | ||
| Aplaviroc (AK 602), a SDP derivative, is a CCR5 antagonist, with IC50s of 0.1-0.4 nM for HIV-1Ba-L, HIV-1JRFL and HIV-1MOKW. | ||
| M40551 | Nifeviroc | CCR |
| Nifeviroc (nifeviroc) is an orally active CCR5 antagonist for use in HIV-1 infection studies. | ||
| M40607 | CCR7 Ligand 1 | CCR |
| CCR7-Cmp2105 | ||
| CCR7 Ligand 1 (CCR7-Cmp2105) is a human CC chemokine receptor 7 (CCR7) variant ligand and a potent intracellular CCR7 receptor variant antagonist with a Kd value of 3 nM. In addition, CCR7 Ligand 1 also inhibited CCL19 activation with an IC50 value of 7.3 μM. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
